Aprosulate sodium

Drug Profile

Aprosulate sodium

Alternative Names: LW 10082; MW 2837

Latest Information Update: 01 May 2003

Price : $50

At a glance

  • Originator Luitpold Pharmaceuticals
  • Class Anticoagulants; Antithrombotics
  • Mechanism of Action Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Thromboembolism; Thrombosis

Most Recent Events

  • 10 Sep 1997 Phase-I clinical trials for Thrombosis in Germany (SC)
  • 10 Sep 1997 Phase-I clinical trials for Thromboembolism in Germany (SC)
  • 18 Jun 1997 Preclinical development for Thrombosis in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top